Publication on platelets / Články o destičkách

Research group of Cardiovascular and respirator pharmacology and toxicology

Carazo A, Hrubša M, Konečný L, Gunaseelan C, Fadraersada J, Skořepa P, Paclíková M, Musil F, Karlíčková J, Javorská L, Matoušová K, Kujovská-Krčmová L, Šmahelová A, Blaha V & Mladěnka P. Correlations among different platelet aggregation pathways in a group of healthy volunteers. Platelets 2024;35(1): 2336093 (IF₂₀₂₃3.3, Q2_AIS in HEMATOLOGY)
Konečný L, Hrubša M, Karlíčková J, Carazo A, Javorská L, Matoušová K, Kujovská Krčmová L, Blaha V, Bláha M & Mladěnka P. The impact of convertase subtilisin/kexin type 9 monoclonal antibodies with and without apheresis on platelet aggregation in familial hypercholesterolemia. Cardiovasc Drugs Ther 2024; 38: 959–970 (IF₂₀₂₁ 3.9; Q1_2021/AIS in PHARMACOLOGY & PHARMACY; Q2_2021/AISCARDIAC & CARDIOVASCULAR SYSTEMS)
Konečný L, Hrubša M, Karlíčková J, Carazo A, Javorská L, Matoušová K, Krčmová LK, Šmahelová A, Blaha V, Bláha M, Mladěnka P. The Effect of 4-Methylcatechol on Platelets in Familial Hypercholesterolemic Patients Treated with Lipid Apheresis and/or Proprotein Convertase Subtilisin Kexin 9 Monoclonal Antibodies. Nutrients. 2023; 15(8):1842 (IF₂₀₂₁ 6.7 Q1_2021/IF in Nutrition & Dietetics, Q2_2021/AIS in Nutrition & Dietetics)
Sisa M, Konečný L, Temml V, Carazo A, Mladěnka P, Landa P. SC-560 and mofezolac isosteres as new potent COX-1 selective inhibitors with antiplatelet effect. Arch Pharm (Weinheim). 2023;356(5): e2200549 (IF₂₀₂₁ 4.6, Q2_IFin PHARMACY AND PHARMACOLOGY; CHEMSITRY, MEDICAL; and CHEMISTRY, MULTIDISCIPLINARY)
Carazo A, Hrubša M, Konečný L, Skořepa P, Paclíková M, Musil F, Karlíčková J, Javorská L, Matoušová K, Kujovská Krčmová L, Parvin MS, Šmahelová A, Blaha V & Mladěnka P. Sex-related differences in platelet aggregation: a literature review supplemented with local data from a group of generally healthy individuals. Semin Thromb Hemost 2023; 49(5):488-506 /IF₂₀₂₁ 6.4/ (Q1_IF2021 in Peripheral Vascular Disease, Q2_IF2021 in Hematology)
Hrubša M, Konečný L, Paclíková M, Parvin MS, Skořepa P, Musil F, Karlíčková J, Javorská L, Matoušová K, Krčmová LK, Carazo A, Šmahelová A, Blaha V, Mladěnka P. The Antiplatelet Effect of 4-Methylcatechol in a Real Population Sample and Determination of the Mechanism of Action. Nutrients. 2022; 14(22):4798 (IF₂₀₂₁ 6.7 Q1_2021/IF in Nutrition & Dietetics, Q2_2021/AIS in Nutrition & Dietetics)
Parvin MS, Hrubša M, Fadraersada J, Carazo A, Karlíčková J, Cahlíková L, Chlebek J, Macáková K, Mladěnka P. Can Isoquinoline Alkaloids Affect Platelet Aggregation in Whole Human Blood? Toxins 2022; 14(7):491 /IF₂₀₂₁ 5.0/ (Q1_IF2021 in Toxicology, Q2_IF2021 in Food Science & Technology)
Hrubša M, Alva R, Parvin MS, Macáková K, Karlíčková J, Fadraersada J, Konečný L, Moravcová M, Carazo A, Mladěnka P. Comparison of Antiplatelet Effects of Phenol Derivatives in Humans. Biomolecules. 2022; 12(1):117 /IF₂₀₂₀ 4.9/ (Q2_AIS,2020 in Biochemistry & Molecular Biology)
Hrubša M, Nurjamal K, Carazo A, Nayek N, Karlíčková J, Applová L, Karmakar I, Parvin S, Fadraersada J, Macáková K, Mladěnka P, Brahmachari G. Screening of Synthetic Heterocyclic Compounds as Antiplatelet Drugs. Med Chem. 2022;18(5):536-543 /IF₂₀₂₀ 2.7/
Sirakanyan SN, Hrubša M, Spinelli D, Dias P, Kartsev V, Carazo A, Hovakimyan AA, Pourová J, Hakobyan EK, Karlíčková J, Parvin S, Fadraersada J, Macáková K, Geronikaki A & Mladěnka P. Synthesis of 3,3-dimethyl-6-oxopyrano[3,4-c]pyridines and their antiplatelet and vasodilatory activity. J Pharm Pharmacol 2021, in press, /IF₂₀₁₉ 2.6/
Pourová J, Applová L, Macáková K, Vopršalová M, Migkos T, Bentanachs R, Biedermann D, Petrásková L, Tvrdý V, Hrubša M, Karlíčková J, Křen V, Valentová K & Mladěnka P. The Effect of Silymarin Flavonolignans and Their Sulfated Conjugates on Platelet Aggregation and Blood Vessels Ex Vivo. Nutrients 2019; 11(10): 2286 /IF₂₀₁₈=4.2/
Applová L, Karlíčková J, Warncke P, Macáková K, Hrubša M, Macháček M, Tvrdý V, Fischer D, Mladěnka P. 4-Methylcatechol, a Flavonoid Metabolite with Potent Antiplatelet Effects. Mol Nutr Food Res. 2019; 63 (20): 1900261 /IF₂₀₁₇=5.2/
Migkos T, Applová L, Horký P, Tvrdý V, Karlíčková J, Macáková K, Hrubša M, Catapano MC, Tomanek M, Pour M, Mladěnka P. The influence of microbial isoflavonoid specific metabolites on platelets and transition metals iron and copper. Phytomedicine 2019;62:152974 /IF₂₀₁₇=3.6/
Applová L, Veljovic E, Muratovic S, Karlíčková J, Macáková K, Završnik D, Saso L, Duric K, Hrdina R, Mladěnka P. 9-(4'-dimethylaminophenyl)-2,6,7-trihydroxy-xanthene-3-one is a potentially novel antiplatelet drug antagonizing the effect of thromboxane A2, Med Chem 2018;77:287-292 /IF₂₀₁₆=2.3/
Applová L, Karlíčková J, Říha M, Filipský T, Macáková K, Spilková J, Mladěnka P. The isoflavonoid tectorigenin has better antiplatelet potential than acetylsalicylic acid. Phytomedicine 2017;35:11-7 /IF₂₀₁₆=3.5/
Karlíčková J, Říha M, Filipský T, Macáková K, Hrdina R & Mladěnka P. Antiplatelet effects of flavonoids mediated by inhibition of arachidonic acid based pathway. Planta Med 2016;82(01/02): 76-83 /IF₂₀₁₄=2.2/
Najmanová I, Doseděl M, Hrdina R, Anzenbacher P, Filipský T, Říha M, Mladěnka P. Cardiovascular Effects of Coumarins Besides their Antioxidant Activity. Curr Top Med Chem. 2015;15(9):830-49 /IF₂₀₁₃=3.5/
Macáková K, Řeháková Z, Mladěnka P, Karlíčková J, Filipský T, Říha M, Prasad AK, Parmar VS, Jahodář L, Pávek P, Hrdina R, Saso L. In vitro platelet antiaggregatory properties of 4-methylcoumarins. Biochimie 2012; 94(12): 2681-6 /IF₂₀₁₁=3.0/
Mladenka P, Zatloukalová L, Filipský T, Hrdina R. Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radic Biol Med. 2010;49(6):963-75 /IF₂₀₀₉=6.1/